Bristol Myers Squibb (NYSE:BMY) Stock Rating Lowered by Wall Street Zen

13 Apr 2026, 01:43 by Renee Jackson · The Cerbat Gem

Bristol Myers Squibb (NYSE:BMY – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. HSBC lifted their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Barclays initiated coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $61.71.

Read Our Latest Report on BMY

Bristol Myers Squibb Stock Down 0.0%

BMY opened at $58.61 on Friday. The business has a 50 day moving average price of $59.78 and a 200 day moving average price of $53.24. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm has a market cap of $119.66 billion, a P/E ratio of 16.99, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the firm posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Institutional Trading of Bristol Myers Squibb

Institutional investors and hedge funds have recently modified their holdings of the company. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at $25,000. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. Harbor Capital Advisors Inc. grew its position in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. Finally, Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $31,000. 76.41% of the stock is currently owned by institutional investors.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Cobenfy showing commercial momentum — grew to roughly $155M in 2025 and is outpacing peers, supporting upside potential from new indications. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Positive Sentiment: New R&D collaboration with Oxford BioTherapeutics to discover next‑generation T‑cell engagers for solid tumors — expands BMS’s oncology pipeline and validates external discovery partnerships. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb…
Positive Sentiment: Analyst support: Guggenheim reiterated a Buy rating, which can lend short-term confidence to the stock. Guggenheim Reiterates Buy Rating for Bristol Myers Squibb (NYSE:BMY)
Neutral Sentiment: Dividend resilience noted — BMY highlighted as a recession‑resistant dividend stock, supporting income‑investor interest. 2 Recession Resistant Dividend Stocks to Buy Now While They’re Still Cheap
Neutral Sentiment: Cantor Fitzgerald adjusted its price recommendation history (raised prior levels) but flagged Q1 catalysts are weak—mixed messaging that tempers conviction. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst
Neutral Sentiment: Macro note: BofA says many biopharma names are largely exempt from proposed pharma tariffs — a mild tailwind for the sector. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
Negative Sentiment: Near‑term revenue/earnings caution: a Zacks piece notes BMY’s YTD gains but warns generic erosion and the company’s 2026 sales outlook are reasons for investor caution. BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
Negative Sentiment: Earnings risk: previews and analyst commentary expect a sizable Q1 earnings decline, which increases short‑term downside risk around the upcoming release. Bristol-Myers Squibb Earnings Preview: What to Expect
Negative Sentiment: Some sell‑side adjustments show modestly lower price targets (Bank of America trimmed a target from $68 to $67; other outlets note PT shifts), signaling cautious near‑term sentiment. Benzinga

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.